Scott Edil Pharmacia Ltd. Revenue and Competitors
Estimated Revenue & Valuation
- Scott Edil Pharmacia Ltd.'s estimated annual revenue is currently $34.3M per year.
- Scott Edil Pharmacia Ltd.'s estimated revenue per employee is $100,500
Employee Data
- Scott Edil Pharmacia Ltd. has 341 Employees.
- Scott Edil Pharmacia Ltd. grew their employee count by 8% last year.
Scott Edil Pharmacia Ltd.'s People
Name | Title | Email/Phone |
---|
Scott Edil Pharmacia Ltd. Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $56.6M | 563 | 21% | N/A | N/A |
#2 | $15.6M | 155 | 28% | N/A | N/A |
#3 | $17M | 169 | -11% | N/A | N/A |
#4 | $13.2M | 131 | 8% | N/A | N/A |
#5 | $19.6M | 195 | 10% | N/A | N/A |
#6 | $23.5M | 234 | 7% | N/A | N/A |
#7 | $5.3M | 53 | 0% | N/A | N/A |
#8 | $13M | 129 | -25% | N/A | N/A |
#9 | $20.5M | 204 | 11% | N/A | N/A |
#10 | $11.7M | 116 | 6% | N/A | N/A |
What Is Scott Edil Pharmacia Ltd.?
Scott Edil Pharmacia is a professionally managed group of companies for the manufacturing and marketing of quality pharmaceuticals range of products, since 1996. Scott Edil Pharmacia has delivered on all fronts because of its meticulous planning and marketing over the last five years. It is about to reach a turnover of Rs.100 crore. Today Scott Edil Pharmacia has an ISO 9001-2000 certificate besides WHO-GMP certification. It has nine sections and is manufacturing more that 400 products. It is one of the fastest growing company of India.
keywords:N/AN/A
Total Funding
341
Number of Employees
$34.3M
Revenue (est)
8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Scott Edil Pharmacia Ltd. News
2022-02-22 - Scott-Edil Pharmacia making affordable, accessible quality ... IndiaTV News
Scott-Edil Pharmacia making affordable, accessible quality ... IndiaTV News
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $98.3M | 341 | 10% | N/A |
#2 | $61.8M | 341 | N/A | N/A |
#3 | $61.8M | 341 | N/A | N/A |
#4 | $123.6M | 341 | 7% | N/A |
#5 | $76.7M | 341 | 3% | N/A |